PMID- 1725282
OWN - NLM
STAT- MEDLINE
DCOM- 19920514
LR  - 20190624
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 204
IP  - 2
DP  - 1991 Nov 5
TI  - A pharmacokinetic analysis of 3,4-methylenedioxymethamphetamine effects on 
      monoamine concentrations in brain dialysates.
PG  - 135-40
AB  - Interpretation of the in vivo actions of 3,4-methylenedioxymethamphetamine (MDMA) 
      is complicated by the formation of the active metabolite, 
      3,4-methylenedioxyamphetamine (MDA). This study evaluates the role of MDA in the 
      dopamine releasing actions of (+)-MDMA. In the study, rats were given 
      subcutaneous doses of (+)-MDMA and concentrations of monoamines and their 
      metabolites in striatal dialysate were measured at 15 min intervals. In parallel 
      experiments, plasma concentrations of (+)- and (-)-MDMA and MDA were determined 
      by GC/MS procedures. The time course of MDMA levels was comparable for the two 
      isomers as were their bioavailabilities. In contrast, the plasma levels of MDA 
      were about three times higher after (+)-MDMA. (+)-MDMA caused a rapid increase in 
      striatal dialysate levels of dopamine and decreased extracellular levels of 
      dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA). There was a 
      significant correlation between dopamine concentration in striatal dialysate and 
      plasma MDMA concentration, but not with plasma MDA. These results indicate that 
      MDMA itself has stereoselective actions on dopamine neurons. However, the higher 
      plasma MDA levels after (+)-MDMA may account for part of the enantiomeric 
      differences in the behavioral and neurotoxicological effects of MDMA.
FAU - Hiramatsu, M
AU  - Hiramatsu M
AD  - Department of Pharmacology, UCLA School of Medicine 90024-1735.
FAU - DiStefano, E
AU  - DiStefano E
FAU - Chang, A S
AU  - Chang AS
FAU - Cho, A K
AU  - Cho AK
LA  - eng
GR  - DA02426/DA/NIDA NIH HHS/United States
GR  - DA04206/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Biogenic Monoamines)
RN  - 102-32-9 (3,4-Dihydroxyphenylacetic Acid)
RN  - 333DO1RDJY (Serotonin)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - 54-16-0 (Hydroxyindoleacetic Acid)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - VTD58H1Z2X (Dopamine)
RN  - X77S6GMS36 (Homovanillic Acid)
SB  - IM
MH  - 3,4-Dihydroxyphenylacetic Acid/metabolism
MH  - 3,4-Methylenedioxyamphetamine/*analogs & 
      derivatives/metabolism/pharmacokinetics/pharmacology
MH  - Animals
MH  - Biogenic Monoamines/*metabolism
MH  - Biological Availability
MH  - Brain Chemistry/*drug effects
MH  - Corpus Striatum/drug effects/metabolism
MH  - Dialysis
MH  - Dopamine/metabolism
MH  - Gas Chromatography-Mass Spectrometry
MH  - Homovanillic Acid/metabolism
MH  - Hydroxyindoleacetic Acid/metabolism
MH  - Injections, Subcutaneous
MH  - Isomerism
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Serotonin/metabolism
EDAT- 1991/11/05 00:00
MHDA- 1991/11/05 00:01
CRDT- 1991/11/05 00:00
PHST- 1991/11/05 00:00 [pubmed]
PHST- 1991/11/05 00:01 [medline]
PHST- 1991/11/05 00:00 [entrez]
AID - 0014-2999(91)90697-O [pii]
AID - 10.1016/0014-2999(91)90697-o [doi]
PST - ppublish
SO  - Eur J Pharmacol. 1991 Nov 5;204(2):135-40. doi: 10.1016/0014-2999(91)90697-o.